Amgen

• 10-QQ2 FY2026Mixed

  Filed Aug 4

  Repatha, EVENITY and TEZSPIRE gains drove growth as biosimilars eroded Prolia and XGEVA sales.

  • Revenue$10.1BYoY +9.5%
  • Net income$2.4BYoY +65.9%

• 8-KPositiveEarningsNew guidance

  Filed Aug 4

  Repatha and other growth drivers lifted product sales, while biosimilar competition and lower pricing weighed on Prolia.

• 8-KCybersecurity incident

  Filed Jul 31

  Third-party cloud data theft involved proprietary and patient health information; file volume and potential sensitivity prompted a materiality finding.

• 8-KShareholder vote

  Filed May 20

  Shareholders rejected an independent board chairman requirement and re-elected all director nominees.

• 8-KCEO/CFO changeExecutive pay

  Filed May 19

  Thomas Dittrich returns from Galderma to succeed retiring CFO Peter Griffith; Griffith stays through January 2027 to support the transition.

• 10-QQ1 FY2026Mixed

  Filed Apr 30

  Repatha, UPLIZNA and IMDELLTRA growth helped offset Prolia and XGEVA biosimilar erosion as pipeline and manufacturing spending rose.

  • Revenue$8.6BYoY +5.8%
  • Net income$1.8BYoY +5.1%

• 8-KEarningsNew guidance

  Filed Apr 30

  FDA proposes withdrawing TAVNEOS approval; Amgen plans to contest as the drug stays on the market during the process.

• 8-KLeadership change

  Filed Apr 22

  David Reese’s retirement brings Sean Bruich into the CTO role and redistributes duties to further integrate science, technology and data.

• 8-KDebt financing

  Filed Feb 19

  Senior unsecured note issuance adds debt across four maturities extending to 2056.

• 10-KFY2025Impairment / charge

  Filed Feb 13

  Repatha and TEZSPIRE growth outweighed ENBREL’s price-led decline; Prolia and XGEVA biosimilars threaten faster erosion.

  • Revenue$36.8BYoY +10.0%
  • Net income$7.7BYoY +88.5%

• 8-KEarningsNew guidanceImpairment / chargeDeal terminated

  Filed Feb 3

  FDA sought voluntary U.S. withdrawal of TAVNEOS over trial re-adjudication and liver toxicity concerns; Amgen declined.

• 8-KNegativeDeal terminated

  Filed Jan 30

  Kyowa Kirin license and collaboration agreement set to end upon regulatory approval.

Coverage: 10-K filings filed since Feb 13, 2026; 10-Q since Apr 30, 2026; 8-K since Jan 30, 2026.

Request longer coverage

Company data: Wikidata Q470517